Barclays »

Sab Biotherapeutics shares owned by Barclays

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.9k 496 3.83
2024-09-30 $0 10 0.00

More positions owned by Barclays

Ishares Tr Opt Put Option (EEM)
Microsoft Corporation (MSFT)
STATE STR SPDR S&ampP 500 ETF T Opt Call Option (SPY)
NVIDIA Corporation (NVDA)
Invesco Qqq Tr Opt Call Option (QQQ)
Ishares Tr Fund (IWM)
Apple (AAPL)
Amazon (AMZN)
Alphabet Inc Class A cs (GOOGL)
Facebook Inc cl a (META)
Broadcom (AVGO)
Tesla Motors (TSLA)
Ishares Tr Opt Put Option (HYG)
JPMORGAN CHASE &amp Opt Call Option (JPM)
Alphabet Inc Class C cs (GOOG)

View all positions for Barclays

Top funds holding Sab Biotherapeutics

Vivo Capital
Caligan Partners
Perceptive Advisors
Commodore Capital
RA Capital Management
Balyasny Asset Management
Adage Capital Partners GP
Millennium Management
Woodline Partners
Vanguard Capital Management
Sessa Capital IM
Boothbay Fund Management
Ameriprise Financial
Ensign Peak Advisors
Soleus Capital Management

View all funds holding Sab Biotherapeutics